Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing

AmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.com

FierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 win

Samsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce Pharma

NovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma

FierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQvia

BioWorldBiggest gainers and losers for April 27-May 1, 2026

Endpoints NewsCelcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series A

AmgenGuggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge? - 24/7 Wall St.

FierceBiotechWindward catches $165M breeze to fuel long-acting TSLP ambitions

BioPharma DiveWith $97M, Latus pursues a different kind of Huntington’s gene therapy

Endpoints NewsBiotech has a new startup model: Small team, big check and Chinese assets

Thermo FisherThermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract Pharma